IBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
IBIO, INC. (IBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $6.30 per share for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2023-09-27
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $6.30, a 72.90% decline from fiscal 2022.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $23.25, a 25.60% decline from fiscal 2021.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2021 was $31.25.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2023-06-30 | $6.30 10-K · filed 2023-09-27 |
| 2022-06-30 | $23.25 10-K · filed 2023-09-27 |
| 2021-06-30 | $31.25 10-K · filed 2022-10-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |